A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03466411 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1409

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Guselkumab Dose 1
DRUG: Guselkumab Dose 2
DRUG: Guselkumab Dose 3
DRUG: Guselkumab Dose 4
DRUG: Guselkumab Dose 5
DRUG: Guselkumab
DRUG: Ustekinumab
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC